Investigational drug · Phase 2
CD19 t-haNK- Administration
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Relapsed B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non Hodgkin Lymphoma.
Phase 2Last checked: Nov 20, 2026Latest source record: May 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "CD19 t-haNK- Administration"
First trial start
2025
Nov 11, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CD19 t-haNK- Administration", any sponsor or status.
Conditions studied
As listed on its trial records.
- Relapsed B-Cell Non-Hodgkin Lymphoma
- Relapsed B-Cell Non Hodgkin Lymphoma
Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "CD19 t-haNK- Administration" as an intervention, largest first.
- Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin LymphomaNot yet recruiting
ImmunityBio, Inc.Industry
NCT07477366 · 20 participants (planned) · Start Apr 2026 · Primary completion Dec 2027
Drug: CD19 t-haNK- IV Administration; N-803 and 1 more · For: Relapsed B-Cell Non-Hodgkin Lymphoma
ImmunityBio, Inc.Industry
NCT07125872 · 20 participants (planned) · Start Nov 11, 2025 · Primary completion May 25, 2027
Drug: CD19 t-haNK- IV Administration · For: Relapsed B-Cell Non Hodgkin Lymphoma
Sites: Johannesburg, South Africa; Pretoria, South Africa
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.